SHAREHOLDER Inform: Pomerantz Legislation Company Investigates Promises On Behalf of Traders of Penumbra, Inc. – PEN

SHAREHOLDER Inform: Pomerantz Legislation Company Investigates Promises On Behalf of Traders of Penumbra, Inc. – PEN

The MarketWatch News Division was not associated in the creation of this information.

NEW YORK, Feb. 4, 2021 /PRNewswire by using COMTEX/ —
NEW YORK, Feb. 4, 2021 /PRNewswire/ — Pomerantz LLP is investigating promises on behalf of investors of Penumbra, Inc. (“Penumbra” or the “Company”) (NYSE: PEN).  This sort of traders are advised to get hold of Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.

The investigation fears whether Penumbra and specified of its officers and/or directors have engaged in securities fraud or other illegal enterprise methods. 

[Click here for information about joining the class action] 

On September 14, 2020, the Basis for Economic Journalism (the “FFJ”) revealed an report boosting really serious concerns about the safety profile of the Company’s Jet 7 Xtra Flex catheter, a flagship solution.  The FFJ noted that considering the fact that the product’s introduction in mid-2019, a U.S. Food and Drug Administration database had recorded 12 deaths associated with the product’s use.  On this news, Penumbra’s inventory price fell by practically 3%, from $199.43 for each share on September 13, 2020 to $193.66 for every share on September 14, 2020, a decline of $5.77 for every share. 

On November 9, 2020, Quintessential Cash Administration (“QCM”) launched a presentation, entitled “Penumbra and Its Killer Catheter,” detailing injuries and deaths resulting from Jet 7 Xtra Flex malfunctions, and highlighting that Penumbra experienced not issued any observe to U.S. health care companies relating to the device’s security troubles until finally a lot more than a thirty day period right after the Firm’s Japanese distributor despatched out a warning, and more than 9 months soon after the first client died from the product’s malfunction.  QCM accused Penumbra of a “seemingly blatant disregard for patients’ lives” and in essence “blaming physicians” for the devices’ style flaws.  On November 23, 2020, the Journal of NeuroInterventional Surgery printed an short article presenting the cases of 3 people who experienced as a final result of Jet 7 Xtra Flex gadget malfunctions, such as two fatalities.  As information of the journal post circulated over the subsequent two days, Penumbra’s inventory price fell from $254.71 on November 23, 2020 to $224.12 on November 25, 2020, a drop of about 12%. 

On December 8, 2020, QCM issued a different report reiterating its prior assertions and disclosing more specifics about the Jet 7 Xtra Flex’s protection problems.  Among the other factors, QCM’s 2nd report questioned the validity and independence of the scientific exploration supporting the Jet 7 Xtra Flex’s security, and accused the Corporation of applying a bogus writer to publish scientific studies concerning the purported security and efficacy of its products and solutions.  In reaction, Penumbra’s inventory price fell by 9%, from $224.02 for each share on December 7, 2020 to $204.07 for each share on December 8, 2020, a drop of $19.95 for each share.

Lastly, on December 15, 2020, after the current market closed, the Corporation issued a push release announcing that it was issuing an “urgent” recall of the Jet 7 Xtra Flex simply because the catheter “could become susceptible to distal idea hurt throughout use” which could guide to injury or loss of life.  On a conference call held the very same day, the Firm’s CEO acknowledged that the product’s design “ma[de] the catheter inclined to failure in certain scenarios” and that the Company’s “steps to assure the safe use of the products . . . ended up not ready to thoroughly address the dangers.”  In reaction, Penumbra’s stock price fell by 7%, from $188.82 for each share on December 15, 2020 to $174.98 for every share on December 16, 2020, a decrease of $13.84 for every share.

The Pomerantz Company, with workplaces in New York, Chicago, Los Angeles, and Paris is acknowledged as just one of the premier corporations in the regions of corporate, securities, and antitrust course litigation. Started by the late Abraham L. Pomerantz, acknowledged as the dean of the class motion bar, the Pomerantz Company pioneered the discipline of securities class actions. Now, much more than 80 decades afterwards, the Pomerantz Agency proceeds in the custom he set up, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered several multimillion-dollar damages awards on behalf of course members. See

Get hold of:

Robert S. Willoughby
Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

Check out first articles:—pen-301222815.html

Resource Pomerantz LLP


Is there a difficulty with this push release? Get in touch with the source company Comtex at [email protected]. You can also speak to MarketWatch Purchaser Company by way of our Purchaser Centre.

Copyright (C) 2021 PR Newswire. All rights reserved

The MarketWatch Information Section was not concerned in the development of this content.